Email this page: News Release
Data Safety and Monitoring Board Recommends Celldex's Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Celldex Therapeutics, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Celldex Therapeutics, Inc. prevent automated submissions.